In this episode of Lipid Insights, we explore the NLA's recent expert meta-analysis, "Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials."

Lead author Dinesh K. Kalra, MD, MBA and key author Kevin C. Maki, PhD, CLS, MNLA join host Alan S. Brown, MD, MHA, MNLA to examine the relationship between LDL-C reduction and major adverse cardiovascular events in primary prevention trials. Together, they break down the findings, clinical implications, and why early LDL-C lowering remains central to preventing first cardiovascular events.

Read the meta-analysis: https://www.lipidjournal.com/article/S1933-2874(26)00039-5/fulltext

In this episode of Lipid Insights, host Dr. Peter Jones is joined by renowned experts Robert H. Eckel, MD, FNLA and Samuel M. Kim, MD for a thoughtful discussion on the complex relationship between obesity, weight loss, and cardiometabolic health.

Hosted by Dave Dixon, PharmD, CLS, FNLA, this episode features an in-depth discussion with three key authors of the NLA’s new statement providing updated guidance on diagnosis, management, and treatment of FH. Together, they review the most important updates in the new guidance, including recommendations for earlier identification, the role of genetic testing and cascade screening, updated LDL-cholesterol treatment targets, and the integration of newer lipid-lowering therapies. The conversation also addresses practical considerations for managing FH across the lifespan, from pediatric care to special populations, with a focus on translating evidence-based recommendations into real-world clinical practice.

You can watch the video version of this podcast HERE.

You can read the official NLA consensus statement published open-access in the Journal of Clinical Lipidology HERE.

Podcast listeners can claim credit for listening to the podcast HERE.
This podcast has been approved for AMA PRA Category 1 Credit™. This activity is eligible for ACPE, ANCC, and CDR credit.